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Summary
Background: Bernard-Soulier syndrome (BSS) is a se-
vere congenital bleeding disorder characterized by 
thrombocytopenia, thrombocytopathy and decreased 
platelet adhesion. BSS results from genetic alterations of 
the glycoprotein (GP) Ib/IX/V complex. Methods: We re-
port on a patient demonstrating typical BSS phenotype 
(thrombocytopenia with giant platelets, bleeding symp-
toms). However, BSS was not diagnosed until he 
reached the age of 39 years. Results: Flow cytometry of 
the patient’s platelets revealed absence of GPIb/IX/V re-
ceptor surface expression. In addition, immunofluores-
cence analysis of patient’s platelets demonstrated very 
faint staining of GPIX. A novel homozygous deletion 
comprising 11 nucleotides starting at position 1644 of 
the GPIX gene was identified using molecular genetic 
analysis. Conclusions: The novel 11-nucleotide deletion 
(g.1644_1654del11) was identified as causing the bleed-
ing disorder in the BSS patient. This homozygous dele-
tion includes the last 4 nucleotides of the Kozak se-
quence as well as the start codon and the following 4 
nucleotides of the coding sequence. The Kozak sequence 
is a region indispensable for the initiation of the protein 
translation process, thus preventing synthesis of func-
tional GPIX protein in the case of deletion.
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Zusammenfassung
Hintergrund: Das Bernard-Soulier-Syndrom (BSS) ist 
eine angeborene Blutungsstörung, die mit Thrombozyto-
penie, Thrombozytopathie und verminderter Thrombo-
zytenadhäsion assoziiert ist. BSS wird durch genetische 
Veränderungen des Glykoprotein(GP)-Ib/IX/V-Komplexes 
verursacht. Methoden: Wir berichten über einen Patien-
ten mit typischem BSS-Phänotyp (Thrombozytopenie 
mit Riesenthrombozyten, Blutungssymptome). Dennoch 
wurde die Diagnose BSS erst im Alter von 39 Jahren ge-
stellt. Ergebnisse: Die Durchflusszytometrie der Throm-
bozyten des Patienten ergab eine fehlende Oberflächen-
expression des GPIb/IX/V-Rezeptors. Zusätzlich zeigten 
Immunfluoreszenz-Analysen der Thrombozyten eine nur 
sehr schwache Anfärbung von GPIX. In der molekular-
genetischen Analyse wurde eine noch nicht bekannte 
homozygote Deletion von 11 Nukleotiden (beginnend an 
Position 1644 im GPIX-Gen) identifiziert. Schlussfol-
gerungen: Diese neue Deletion von 11 Nukleotiden 
(g.1644_1654del11) wurde als Ursache für die vermehrte 
Blutungsneigung bei dem BSS-Patienten identifiziert. 
Von der homozygoten Deletion betroffen sind die letzten 
4 Nukleotide der Kozak-Sequenz sowie das Startkodon 
und weitere 4 Nukleotide des kodierenden Bereichs. Die 
Kozak-Sequenz ist unerlässlich für die Initiation der 
Translation in der Proteinbiosynthese, so dass die bei 
dem Patienten nachgewiesene Deletion die Synthese 
des funktionellen GPIX-Proteins verhindert.
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platelet and red blood cell transfusions at several occasions which led to 
the development of HLA and antiE antibodies. At the age of 39, the pa-
tient suffered from severe gastrointestinal bleeding at different sites lead-
ing to admission to the University Hospital Dresden. He required massive 
blood transfusions, ligature of the gastroduodenal artery, duodenotomy, 
and partial gastrectomy (Billroth-I resection), which finally led to a stop 
of the bleeding. Because of severe thrombocytopenia and the detection of 
giant platelets in the blood smear (fig. 1), BSS was suspected and flow 
cytometry analysis was initiated confirming the diagnosis of BSS. The 
presence of hereditary macrothrombocytopenia caused by a defect of 
non-muscle myosin type IIA, such as May-Hegglin anomaly, Sebastian 
platelet syndrome, and Fechtner syndrome, was ruled out by immunoflu-
orescence staining. Extended coagulation diagnostics showed normal val-
ues for the global tests of hemostasis (prothrombin time, activated partial 
thromboplastin time (aPTT)), fibrinogen, coagulation factors VIII and 
XIII, VWF antigen, and collagen binding activity. Concerning the family 
history, the patient reported about the suspected diagnosis of chronic im-
mune thrombocytopenia in his sister. She died at the age of 
5 years most probably caused by serious perioperative bleeding after 
splenectomy. No bleeding diathesis was observed in the patient’s parents 
and the patient’s 2 daughters.
Introduction
The basic diagnostic criteria for Bernard-Soulier syndrome 
(BSS) are thrombocytopenia with giant platelets, decreased 
von Willebrand factor(VWF)-dependent platelet adhesion to 
the subendothelium, and autosomal recessive inheritance. 
BSS has an estimated prevalence of one in a million live 
births. Hallmark of the disease is an aberrant platelet attach-
ment to the vessel wall due to quantitative or qualitative de-
fects of the glycoprotein (GP) Ib/IX/V complex [1]. Physio-
logically, VWF and its platelet surface receptor GPIb/IX/V 
play a critical role in hemostasis by initiating thrombus for-
mation and arrest of platelets at the site of vascular injury [2]. 
Clinically, BSS typically presents with epistaxis, petechiae, or 
gingival bleeding in infancy. The onset of the disease can vary. 
Later symptoms usually include menorrhagia, gastrointestinal 
or genitourinary bleeding. Trauma or surgical procedures es-
pecially in mucosal regions may also lead to excessive bleed-
ing. The severity of bleeding symptoms varies substantially 
among patients [3]. Bleeding time may range from borderline 
normal up to significantly prolonged. Platelet counts can be 
within normal limits or severely decreased [4]. Laboratory 
hallmark are giant platelets, impaired platelet agglutination 
after stimulation with ristocetin, and normal platelet aggrega-
tion with other agonists. GPIb/IX/V surface expression can be 
decreased or absent, or the function of GPIb/IX/V can be re-
duced [5, 6].
The products of 4 distinct genes (GPIbα, GPIbβ, GPIX, 
GPV) assemble within the maturing megakaryocytes to form 
the GPIb/IX/V complex in a 2:2:2:1 stochiometry as present in 
the platelet membrane [1, 7, 8]. GPIbα, GPIbβ and GPIX are 
closely associated and are all required for efficient biosynthe-
sis of the platelet receptor. Mutations within GPIbα, GPIbβ 
and GPIX mostly prevent constitution and/or trafficking of 
the complex through the Golgi apparatus and endoplasmic re-
ticulum [1]. GPV is more loosely associated with the complex, 
and no case of BSS has been reported with a genetic defect in 
the GPV gene [9]. So far, about 50 genetic causes for BSS 
have been described mostly affecting GPIbα. However, most 
European patients are affected by mutations in GPIX (table 
1). Interestingly, GPIX gene defects are mainly missense mu-
tations leading to single amino acid substitutions. Only one 
9-nucleotide deletion in GPIX was described leading to an 
amino acid substitution (D86A) followed by the deletion of 
amino acids 87–89 [10]. Here, we report on a patient with a 
novel homozygous 11-nucleotide deletion within exon 3 of 
GPIX which is associated with a severe BSS phenotype.
Patients, Material and Methods
Patient
The male patient suffered from recurrent epistaxis, easy bruising, and 
non-classified severe thrombocytopenia (< 20,000/μl) since infancy. Be-
fore tooth extractions and in case of severe bleeding he had received 





















Fig. 1. Blood smear of the patient: giant platelet is detectable.
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Immunofluorescence Analysis
The patient’s platelets showed very weak immunofluores-
cence staining with a GPIX antibody (indicating GPIX pro-
tein deficiency). Expression of the GPIIb/IIIa complex was 
normal. Aberrant accumulation of non-muscle myosin heavy 
chain (MYH9) in white blood cells, which is typical for 
MYH-9 disorders (May-Hegglin anomaly or Sebastian plate-
let syndrome), was not detected.
Sequencing Analysis 
A novel homozygous 11-nucleotide deletion (TCCCAT-
GCCTG) starting at position 1644 in exon 3 of the GPIX 
gene (g.1644_1654del11) was identified in the patient’s DNA 
(fig. 2). Sequencing results of the GPIbα and GPIbβ genes 
showed no difference compared to the public data base se-
quences. This genetic defect of GPIX leads to a deletion of 
the last 4 nucleotides of the Kozak sequence, the start codon, 
and the following 4 nucleotides of the coding sequence. 
Discussion
In this study, we report on a novel genetic alteration of the 
GPIX gene (g.1644_1654del11) in a patient with a typical 
clinical phenotype of Bernard-Soulier syndrome (BSS). The 
patient suffered from recurrent epistaxis since infancy. Be-
cause of severe gastrointestinal bleeding requiring blood 
transfusions, a Billroth-I resection was performed. Evalua-
tion of the peripheral blood smear revealed giant platelets. 
As other inherited platelet disorders such as MYH-9 disor-
ders (e.g. May-Hegglin anomaly and Sebastian syndrome) 
also show giant platelets, these diseases were ruled out be-
cause the patient’s white blood cells did not show inclusion 
bodies in the blood smear. Using flow cytometry, no surface 
expression of all 3 subunits of the GPIb/IX/V complex 
(GPIbα, GPIbβ and GPIX) was measurable on the patient’s 
platelets. In addition, platelet immunofluorescence staining 
revealed a markedly decreased GPIX protein level indicat-
ing a GPIX gene defect.
The four subunits assembling to the GPIb/IX/V complex 
belong to the leucine-rich family of proteins and are exclu-
sively expressed in platelets [9]. Lack of a single subunit 
Flow Cytometry Analyses
Flow cytometry analyses were performed using the ADIAflo™ PLATE-
LET GPIb/IX/V Kit (American Diagnostica GmbH, Pfungstadt, Ger-
many) according to the manufacturer’s recommendations. Platelet sur-
face exposure of GPIbα (CD42b), GPIX (CD42a), and GPV (CD42d) 
was measured at the resting state using monoclonal antibodies (CD42b 
clone SZ2; CD42a clone SZ1; CD42d clone SW16).
Immunofluorescence Microscopy
Platelet immunofluorescence analysis with monoclonal antibodies against 
GPIX (CD42a), GPIIb/IIIa, GPIa, and non-muscle myosin IIa was per-
formed as described before [11, 12].
Isolation and Amplification of Genomic DNA
Genomic DNA was isolated from EDTA blood using the DNA Kit from 
Qiagen (Qiagen GmbH, Hilden, Germany). All exons of the genes en-
coding GPIbα, GPIbβ and GPIX were amplified by polymerase chain 
reaction using intronic primers. The amplification was carried out under 
conditions described previously [13]. Purified DNA fragments were di-
rectly sequenced. The oligonucleotides used to amplify a 353-bp fragment 
encompassing exon 2 and 3 of the GPIX gene (accession no. M80478) 




The platelet count revealed severe thrombocytopenia with 
8,000–21,000 platelets/μl, and the mean platelet volume was 
determined as > 12 fl. The blood smear demonstrated giant 
platelets. Platelet aggregometry was not possible because of 
the severe thrombocytopenia. 
Analyses of the Platelet GPIb/IX/V Receptor and von  
Willebrand Factor
In contrast to a healthy platelet donor, there was no surface 
expression of GPIb/IX/V measurable on the patient’s plate-
lets (table 2). The mean fluorescence intensity (MFI) meas-
ured with CD42a, CD42b and CD42d of the 2 daughters’ 
platelets was slightly decreased compared to the healthy con-
trol. Platelet count and receptor counts per platelet were 
within the normal range. Von Willebrand syndrome was ruled 
out in the patient (normal values for VWF antigen, collagen-
binding capacity, VWF multimeric analysis, and factor VIII 
activity).
Parameter Platelet count × 109/l MFI (arbitrary unit) Receptors per platelet
CD42a CD42b CD42d CD42a CD42b CD42d
Patient  14  1.10  0.63  1.01 600  0 400
Daughter 1 266 18.1 14.5  7.77 34,100 27,100 14,000
Daughter 2 326 17.1 12.9  7.29 32,200 24,100 13,200
Control 254 56.6 49.0 20.0 37,800 43,800 14,800
Normal range 150–400 27,000–49,000 20,000–32,000 8,000–16,000
MFI = Mean fluorescence intensity.
Table 2. Flow cytom-
etry analyses of the 
platelet GPIb/IX/V 
receptor
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however, this site varies on different mRNAs in vivo (e.g. 
GPIX mRNA: tgtCccAUGC). Some nucleotides in this se-
quence are more important than others: the ‘AUG’ is essen-
tial since it is the actual initiation codon encoding a methio-
nine amino acid at the N-terminus of the protein. For a 
‘strong’ consensus, the nucleotides at positions +4 (i.e. G in 
the consensus) and –3 (i.e. either A or G in the consensus) 
must both match the consensus. An ‘adequate’ consensus has 
only 1 of these sites, while a ‘weak’ consensus has neither. The 
cc at positions –1 and –2 are not conserved but contribute to 
the overall strength [15].
Investigating the literature for Kozak sequence mutations/
deletions revealed a –1C>T mutation in the α-tocopherol 
transfer protein (α-TTP) gene causing a decreased level of 
α-TTP expression in a patient with ataxia with vitamin E defi-
ciency [16]. In highly aggressive sporadic breast cancer, a 
G>C mutation in BRCA1 at position –3 was identified [17]. 
Here, the translation efficiency was markedly reduced. Af-
shar-Kharghan et al. [18] described a Kozak sequence poly-
morphism in GPIbα, which is based on the presence of either 
thymine or cytosine at position –5. The less common allele, 
–5C, is associated with a more efficient translation of GPIbα 
mRNA leading to increased expression of the GPIb/IX/V re-
ceptor on the cell membrane [19]. 
(GPIbα, GPIbβ, or GPIX) dramatically decreases surface ex-
pression of the whole complex. While most mutations were 
identified in the GPIbα gene, several mutations affecting the 
GPIX peptide have also been described in BSS patients. Al-
most all GPIX gene defects represent single nucleotide muta-
tions within the coding sequence. Only 1 case with a 9-nucle-
otide deletion in the coding region of GPIX has been de-
scribed [10]. This in-frame deletion resulted in the substitu-
tion of amino acid 86 (D86A) and deletion of amino acids 
87–89. This female BSS patient was first investigated at the 
age of 6 years when she presented iron-deficiency anemia 
 following recurrent epistaxis. She demonstrated prolonged 
bleeding from cuts and spontaneous bruising since early child-
hood. Laboratory tests showed low hemoglobin and ferritin 
levels, decreased platelet count, and giant platelets. 
In the Caucasian patient described in this study, a novel 
11-nucleotide deletion located at the junction of the 5'UTR 
(untranslated region) and the coding sequence of GPIX was 
identified. The start codon (methionine), the first 4 nucle-
otides of the coding sequence, and the last 4 nucleotides of the 
Kozak sequence are affected. The Kozak consensus sequence 
occurs on eukaryotic mRNA and is recognized by the ribos-
ome as the translational start site [14]. The perfect Kozak se-
quence consists of gccRccAUGG with AUG as start codon, 
Fig. 2. Molecular 
genetic analysis 
of GPIX. The pa-
tient’s genomic 
DNA revealed a 
homozygous dele-
tion of 11 nucleotides 
(g.1644_1654del11) at 
the beginning of exon 
3 in the GPIX gene. 
A Sequencing analy-
sis was performed 
with forward (left) 
and reverse (right) 
primer, respectively. 
B The start codon is 
marked with a red 
box. Exon-intron 
structure of the 
GPIX gene demon-
strates the location 
of the deletion. The 
g.1644_1654del11 
deletion (red) results 
in the loss of the last 
4 nucleotides of the 
Kozak sequence (ital-
ics), the start codon 
(bold), and the fol-
lowing nucleotides of 
the coding sequence.
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sis of patient’s platelets revealed GPIX deficiency by using a 
GPIX antibody. Within the N-terminal part of GPIX, two dif-
ferent single amino acid substitutions were described causing 
BSS, one in the signal peptide [21] and one at amino acid 8 
[22], both leading to the absence of the GPIb/IX/V complex at 
the platelet surface. We conclude that the GPIX deletion in 
the described patient prevents proper formation of the GPIb/
IX/V complex. In conclusion, the identified 11-nucleotide de-
letion in the GPIX gene was identified as causative for the 
clinical picture of BSS. Interestingly, the patient was not diag-
nosed until he had reached the age of 39 years although bleed-
ing symptoms such as recurrent epistaxis were present since 
infancy. Therefore, patients with recurrent mucocutaneous 
bleeding symptoms should be especially investigated for dis-
orders of primary hemostasis.
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In the lamin AC (LMNA) gene, a 2-exon deletion causing 
a distinct highly malignant cardiomyopathy was identified 
[20]. This deletion affects the start codon-containing exon and 
an adjacent non-coding exon leading to decreased expression 
of lamin A and C. In addition, they postulate new potential 
translation initiation sites resulting in smaller proteins lacking 
the N-terminal region. 
In this study, we identified a deletion within exon 3 of 
GPIX, including the start codon and the Kozak sequence, 
which has not been described before. As the Kozak sequence 
together with the start codon is indispensable for initiating the 
protein translation process, we postulate that the deletion of 
this region in GPIX severely affects GPIX protein synthesis. 
By scanning the GPIX amino acid sequence, we found one 
additional methionine at position 32. This codon may consti-
tute a new potential translation initiation site demonstrating a 
strong Kozak consensus (gaaAccAUGG). In this case, GPIX 
protein synthesis of a N-terminal truncated GPIX protein 
lacking the signal peptide (aa 1–16) and the first 15 amino 
acids of the extracellular domain (aa 17–147) will occur. Be-
cause the signal peptide is essential for the translation of 
transmembrane/extracellular proteins, its absence will pre-
vent protein translocation to the cell membrane, which may 
lead to degradation. Accordingly, immunofluorescence analy-
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